246 related articles for article (PubMed ID: 2977043)
1. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis.
Telimaa S; Puolakka J; Rönnberg L; Kauppila A
Gynecol Endocrinol; 1987 Mar; 1(1):13-23. PubMed ID: 2972167
[TBL] [Abstract][Full Text] [Related]
3. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
[TBL] [Abstract][Full Text] [Related]
4. [Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors].
Yanagawa Y; Okazaki T; Okamura S; Ueki M; Sugimoto O
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2393-8. PubMed ID: 2526618
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
6. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
7. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
[TBL] [Abstract][Full Text] [Related]
8. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
11. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
12. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
[TBL] [Abstract][Full Text] [Related]
13. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
14. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
15. [Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers].
Ishizaki T; Itoh R; Yasuda J; Yamamoto T; Okada H
Gan To Kagaku Ryoho; 1992 Jun; 19(6):837-42. PubMed ID: 1534983
[TBL] [Abstract][Full Text] [Related]
16. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
17. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
19. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
Feng YJ; Zhang XY
Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
[TBL] [Abstract][Full Text] [Related]
20. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.
Riippa P; Kauppila A; Sundström H; Vihko R
Anticancer Res; 1984; 4(3):109-12. PubMed ID: 6235770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
